## VACCINE CELL SUBSTRATE 2004 practical experience

A safety evaluation of MDCK for influenza vaccine production

J.K. Medema

Solvay Pharmaceuticals BV, The Netherlands



#### Egg-based vaccine manufacture

- 60 year old technology
- yields safe, efficacious vaccine
- breeding of eggs
  - Dependent on flocks vulnerable to diseases
  - Order one year in advance
  - Controlled quality
- egg-based production
  - Open system, manual handling
  - Variation in starting material
  - No advantages for scale-up of production



#### CONTINUOUS CELL LINES - VERO

- Manufacturing logistics
  - -increased flexibility
  - -starting materials in stock
- Manufacturing economics
  - -limiting yields
- Manufacturing consistency
  - -consistent starting materials, cell banking
- Regulatory environment
  - –used for licensed vaccines (polio, rabies)



T4 Suggestion: place information from slides 3 and 4 side by side under each of the 4 headings you have for both vero vs. MDCK

Delete: slide 5 and merely speak to the advantage of MDCK over vero

Template, 6/14/2004

#### CONTINUOUS CELL LINES - MDCK

- Manufacturing logistics
  - -increased flexibility
  - -starting materials in stock
- Manufacturing economics
  - -high yields
  - -economy of scale
- Manufacturing consistency
  - -consistent starting materials, cell banking

- \$ SOLVAY
- Regulatory environment
  - -unprecedented

T5 Combine with slide 4

Template, 6/14/2004

#### CONTINUOUS CELL LINES

**VERO vs. MDCK** 



prior approval of cell line vs. yield



T6 Delete

Delete Template, 6/14/2004

#### Madin Darby Canine Kidney - 1

- derived from a kidney of a normal adult female cocker spaniel, September, 1958, by S.H. Madin and N.B. Darby, University of California,
- submitted to American Type Culture Collection (ATCC) August 1964 at p49 by S.H. Madin and N.B. Darby,
- propagated to working cell bank ATCC CCL-34 at p52 directly from the original depositor ampoules and cryopreserved February 1991.



#### Madin Darby Canine Kidney - 2

- ATCC CCL-34, p52 obtained by Solvay in 1992
- adapted to serum-free conditions in 1992
- banked by BioReliance, Rockville, MD at p56 (MCB) and p57 (WCB) in 1992
- propagated by Solvay to p97 (ECB) in 1992/1993 by methods representative for production



historic track record



### CCL - PERCEIVED RISKS

- Tumorigenicity of CCL-intact cells
- (Oncogenicity of) Adventitious viruses
- Oncogenicity of CCL-DNA



### CCL - PERCEIVED RISKS

- Tumorigenicity of CCL-intact cells
- (Oncogenicity of) Adventitious viruses
- Oncogenicity of CCL-DNA



# TUMORIGENICITY – INTACT CELLS regulatory guidance

ICH Q5D

"cells of known tumorigenic potential do not need to be tested further [...] for products that do not contain live cells and are highly purified, provided that appropriate limits for residual DNA are met"

- CPMP Annex NfG on cell-derived influenza vaccines
- CBER Points to Consider 1993 "human epithelial cells and cells used for live virus vaccine need to be tested for tumorigenicity"
- CBER "risk ≤10-6 per dose acceptable"

Defined-risks approach to regulatory assessment of use of neoplastic cells for viral vaccine manufacture – CBER draft (Lewis, Krause, Peden)




# TUMORIGENICITY – INTACT CELLS practical experience

- Cell line identification (MCB and ECB) isoenzyme and genetic analysis: canine origin
- Tumorigenicity testing (ECB) 10<sup>7</sup> viable cells in athymic nude mice: positive
- Risk-based assessment




# TUMORIGENICITY – INTACT CELLS practical experience





# TUMORIGENICITY – INTACT CELLS practical experience



- \$ SOLVAY
- Quantification of tumorigenic potential
- Validated removal intact cells during product purification

or should this read: "> 6 log reduction"? Template, 6/14/2004 T7

### CCL - PERCEIVED RISKS

- Tumorigenicity of CCL-intact cells
- (Oncogenicity of) Adventitious viruses
- Oncogenicity of CCL-DNA



# ADVENTITIOUS VIRUSES regulatory guidance

Absence of adventitious virus testing in cell bank

Validation of removal / inactivation of model viruses by purification process



# ADVENTITIOUS VIRUSES absence testing

- Aspecific absence of adventitious virus testing (MCB and ECB)
  - in vitro; human, simian and canine cell cultures
  - in vivo; suckling and adult mice, guinea pigs, rabbits and embryonated eggs (allantoic, yolk sac and chorioallantoic)
- Specific absence of adventitious virus testing (MCB and ECB)
  - Retrovirus testing
  - Evaluation of cell bank contaminants (e.g. CAV, CHV, CPV)
    CAP test (n=16)
  - Identification of MDCK susceptibility CAP test (n=16)



no evidence for presence of adventitious viruses



## ADVENTITIOUS VIRUSES validation virus removal/inactivation

#### Model viruses:

- Selection based on relevance (e.g. Influenza)
- dsDNA, (-)ssRNA and (+)ssRNA
- Enveloped and non-enveloped
- Size range 30 300 nm
- Low-medium to medium-high resistance



viral clearance of all model viruses validated redundant clearance capacity shown



# ADVENTITIOUS VIRUSES oncogenicity of MDCK lysate

ICH Q5D

"cells of known tumorigenic potential do not need to be tested further [...] for products that do not contain live cells and are highly purified, provided that appropriate limits for residual DNA are met"

additional oncogenicity testing in newborn and immunocompromised animals



lysate of 10<sup>7</sup> cells does not form tumors in 3 months



## CCL - PERCEIVED RISKS

- Tumorigenicity of CCL-intact cells
- (Oncogenicity of) Adventitious viruses
- Oncogenicity of CCL-DNA



# ONCOGENICITY - CELLULAR DNA regulatory guidance

ICH Q5D

"cells of known tumorigenic potential do not need to be tested further [...] for products that do not contain live cells and are highly purified, provided that appropriate limits for residual DNA are met"

- CPMP Annex NfG on cell-derived influenza vaccines "appropriate assay for residual DNA"
- EP 5.2.3 / WHO "residual DNA < 10 ng/dose for inactivated vaccine"</p>
- CBER "risk ≤10-6 per dose acceptable"

Defined-risks approach to regulatory assessment of use of neoplastic cells for viral vaccine manufacture – CBER draft (Lewis, Krause, Peden)





T2

give year and name of draft guidance Template, 6/11/2004

# ONCOGENICITY - CELLULAR DNA practical experience

no risks at 100 μg/dose

additional oncogenicity testing with MDCK-DNA (ECB) in newborn and immunocompromised animals



100 µg MDCK-DNA does not form tumors in 3 months



# ONCOGENICITY – CELLULAR DNA practical experience

- Residual DNA limit set at 10 ng/dose
- Both process validation and lot release testing
- Actual values below 1 ng/dose
- Actual residual DNA digested to small size



#### Solvay's MDCK cell bank

- Tumorigenicity of intact cells
  - only moderate potential in athymic nude mice
  - not in immunocompentent animals
  - risk-based assessment of presence of TP per dose
  - well below acceptable limit, to be confirmed on full production scale

#### T1


- (Oncogenicity of) Adventitious viruses
  - no evidence for presence in cell bank
  - (redundant) clearance of model viruses validated
  - no known risk associated with lysate of 10<sup>7</sup> cells
- Oncogenicity of MDCK-DNA
  - no known risk associated with 100 μg
  - residual levels <10 ng/dose, digested fragments</li>



T1

what does TP stand for?

Template, 6/11/2004



T9

what does TP stand for? Template, 6/11/2004

#### CC-based influenza virus seed

- Derived from WHO egg-based vaccine virus
  - produced in SPF embryonated eggs
  - tested on bacterial and fungal contamination, mycoplasma and ALV
- Produced on released MDCK cell bank





T8

what does TP stand for? Template, 6/11/2004

#### CC-based influenza virus seed

#### Adventitious agents testing

- bacterial and fungal contamination, mycoplasma
- in vitro: human diploid, simian, canine cell lines
- in vivo: suckling and adult mice, guinea pigs
- risk assessment of possible contaminants (coisolates, susceptibility of eggs and MDCK)




30 PCRs covering 35 human viruses



T11

T11

what does TP stand for? Template, 6/11/2004



T10

what does TP stand for? Template, 6/11/2004